MX355552B - Nueva forma cristalina vii de la agomelatina, sus metodos de preparacion, aplicaciones y composiciones farmaceuticas que la contienen. - Google Patents

Nueva forma cristalina vii de la agomelatina, sus metodos de preparacion, aplicaciones y composiciones farmaceuticas que la contienen.

Info

Publication number
MX355552B
MX355552B MX2013010702A MX2013010702A MX355552B MX 355552 B MX355552 B MX 355552B MX 2013010702 A MX2013010702 A MX 2013010702A MX 2013010702 A MX2013010702 A MX 2013010702A MX 355552 B MX355552 B MX 355552B
Authority
MX
Mexico
Prior art keywords
crystal form
preparation
agomelatine
pharmaceutical composition
composition containing
Prior art date
Application number
MX2013010702A
Other languages
English (en)
Other versions
MX2013010702A (es
Inventor
Shan Hanbin
Yuan Zhedong
Huang Yu
Yu Xiong
Zhu Xueyan
Tong Ling
Original Assignee
Shanghai Inst Of Pharmaceutical Industry Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46855966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX355552(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shanghai Inst Of Pharmaceutical Industry Star filed Critical Shanghai Inst Of Pharmaceutical Industry Star
Publication of MX2013010702A publication Critical patent/MX2013010702A/es
Publication of MX355552B publication Critical patent/MX355552B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Glass Compositions (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)

Abstract

La presente invención proporciona el nuevo cristal de agomelatina de tipo VII, sus métodos de preparación, su aplicación y sus composiciones farmacéuticas. La pureza de cristal, la estabilidad de los polimorfos y la buena reproducibilidad y su método de preparación son mejores que en la mayoría de los informes existentes respecto de estabilidad y solubilidad de la forma cristalina. Por lo tanto, la presente invención proporciona un cristal VII que resulta ventajoso en la preparación.
MX2013010702A 2011-03-23 2012-03-22 Nueva forma cristalina vii de la agomelatina, sus metodos de preparacion, aplicaciones y composiciones farmaceuticas que la contienen. MX355552B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011100708280A CN102690210A (zh) 2011-03-23 2011-03-23 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
PCT/CN2012/072816 WO2012126385A1 (zh) 2011-03-23 2012-03-22 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物

Publications (2)

Publication Number Publication Date
MX2013010702A MX2013010702A (es) 2013-10-01
MX355552B true MX355552B (es) 2018-04-23

Family

ID=46855966

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010702A MX355552B (es) 2011-03-23 2012-03-22 Nueva forma cristalina vii de la agomelatina, sus metodos de preparacion, aplicaciones y composiciones farmaceuticas que la contienen.

Country Status (32)

Country Link
US (1) US9527803B2 (es)
EP (1) EP2690087B1 (es)
JP (1) JP6203170B2 (es)
KR (1) KR20130136544A (es)
CN (2) CN102690210A (es)
AR (1) AR085543A1 (es)
AU (1) AU2012231547B2 (es)
BR (1) BR112013024219A2 (es)
CA (1) CA2829687C (es)
CY (1) CY1119625T1 (es)
DK (1) DK2690087T3 (es)
EA (1) EA023297B1 (es)
ES (1) ES2650604T3 (es)
GE (1) GEP20156386B (es)
HK (1) HK1193087A1 (es)
HR (1) HRP20171831T1 (es)
HU (1) HUE037264T2 (es)
LT (1) LT2690087T (es)
MA (1) MA34958B1 (es)
MD (1) MD4391C1 (es)
ME (1) ME02921B (es)
MX (1) MX355552B (es)
MY (1) MY185235A (es)
NO (1) NO2690087T3 (es)
PL (1) PL2690087T3 (es)
PT (1) PT2690087T (es)
RS (1) RS56444B1 (es)
SG (1) SG193300A1 (es)
SI (1) SI2690087T1 (es)
UA (1) UA113058C2 (es)
WO (1) WO2012126385A1 (es)
ZA (1) ZA201306760B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
DK3027588T3 (da) * 2013-07-29 2020-07-06 Servier Lab Komplekser af agomelatin og sulfonsyre, fremgangsmåde til deres fremstilling og lægemiddelsammensætninger som indeholder dem
KR101470794B1 (ko) 2014-06-30 2014-12-08 순천향대학교 산학협력단 아고멜라틴 공결정의 제조 방법 및 이를 포함하는 조성물
PL3075724T3 (pl) 2015-03-31 2023-12-27 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Stała postać agomelatyny
EP3466923A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Process for the preparation of agomelatine in crystalline form
EP3466413A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Pharmaceutical composition containing agomelatine and process for the preparation thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US7498466B2 (en) * 2004-02-13 2009-03-03 Les Laboratoires Servier Process for the synthesis and crystalline form of agomelatine
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889522B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889521B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
US7358395B2 (en) * 2005-08-03 2008-04-15 Les Laboratories Servier Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it
CN101585779B (zh) 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
CN101781225A (zh) * 2009-11-21 2010-07-21 浙江华海药业股份有限公司 一种阿戈美拉汀晶形a制备方法
EP2319827A1 (en) 2009-11-09 2011-05-11 Ratiopharm GmbH Process for the production of polymorph form I of agomelatine
CN101704763B (zh) 2009-11-25 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀i型晶体的制备方法
CN101781226B (zh) * 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN101792400B (zh) * 2010-03-16 2013-01-30 华东师范大学 一种阿戈美拉汀的合成方法
CN101921205B (zh) * 2010-08-30 2013-11-20 江苏恩华药业股份有限公司 阿戈美拉汀ⅰ晶型的制备方法
CN102452951B (zh) * 2010-10-25 2014-02-19 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物

Also Published As

Publication number Publication date
NO2690087T3 (es) 2018-01-27
MD20130073A2 (en) 2014-03-31
MD4391B1 (ro) 2016-01-31
KR20130136544A (ko) 2013-12-12
AU2012231547A8 (en) 2013-10-24
PL2690087T3 (pl) 2018-01-31
NZ615707A (en) 2016-02-26
MX2013010702A (es) 2013-10-01
CN103476742A (zh) 2013-12-25
SI2690087T1 (sl) 2017-12-29
AU2012231547B2 (en) 2015-11-19
SG193300A1 (en) 2013-10-30
HUE037264T2 (hu) 2018-08-28
CA2829687C (en) 2016-08-09
ES2650604T3 (es) 2018-01-19
WO2012126385A1 (zh) 2012-09-27
EA023297B1 (ru) 2016-05-31
DK2690087T3 (en) 2017-12-04
EP2690087A4 (en) 2014-09-17
MY185235A (en) 2021-04-30
CN103476742B (zh) 2015-04-29
CN102690210A (zh) 2012-09-26
HRP20171831T1 (hr) 2017-12-29
US20140011883A1 (en) 2014-01-09
MA34958B1 (fr) 2014-03-01
RS56444B1 (sr) 2018-01-31
MD4391C1 (ro) 2016-08-31
ZA201306760B (en) 2014-05-28
EP2690087B1 (en) 2017-08-30
AR085543A1 (es) 2013-10-09
BR112013024219A2 (pt) 2016-12-20
GEP20156386B (en) 2015-10-26
AU2012231547A1 (en) 2013-10-03
US9527803B2 (en) 2016-12-27
CA2829687A1 (en) 2012-09-27
HK1193087A1 (en) 2014-09-12
JP2014516341A (ja) 2014-07-10
UA113058C2 (xx) 2016-12-12
PT2690087T (pt) 2017-10-04
CY1119625T1 (el) 2018-04-04
EP2690087A1 (en) 2014-01-29
EA201301066A1 (ru) 2014-02-28
LT2690087T (lt) 2017-10-25
ME02921B (me) 2018-10-20
JP6203170B2 (ja) 2017-09-27

Similar Documents

Publication Publication Date Title
MX355428B (es) Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa.
MX355552B (es) Nueva forma cristalina vii de la agomelatina, sus metodos de preparacion, aplicaciones y composiciones farmaceuticas que la contienen.
EA201201294A1 (ru) Гидрат гидрохлорида агомелатина и его получение
MY160460A (en) Agomelatine hydrochloride hydrate and preparation thereof
MX358096B (es) Composiciones azeotropicas y similares a azeotropo de eteres de metil perfluorohepteno y trans-1, 2-dicloroetileno y usos de estas.
MD20120050A2 (en) New agomelatine cocrystals, process for their preparation and pharmaceutical compositions containing them
MX349373B (es) Nuevos derivados de pirazina.
MY169064A (en) Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same
MX355551B (es) Cristal mixto de agomelatina (forma-viii), sus métodos de preparación y aplicaciones y composiciones farmacéuticas que le contienen.
MX366651B (es) Forma a cristalina de (r)-2-((3-(3-aminopiperidin-1-il)-6-metil-5- oxo-1,2,4-triazin-4(5h)-il)metil)-4-fluorobenzonitrilo monobenzoato y método de preparación del mismo y composición farmacéutica que comprende la misma.
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
EA201201293A1 (ru) Гидрат гидробромида агомелатина и его получение
ECSP13013043A (es) Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma
MX2013013403A (es) Modificaciones cristalinas estables de cloruro de dotap.
MX2015005059A (es) Fase cristalina de (3s,3s') 4,4'-disulfanodiilbis(acido 3-aminobutano-1-sulfonico) con l-lisina.
MD4258B1 (en) The use of biologically active coordinative compounds of copper(II) with 4-(methoxyphenyl)thiosemicarbazones of 2-benzoylpyridine as inhibitors of Candida albicans
EA201400022A1 (ru) Способ получения кристаллических форм агомелатина и его новый полиморф
PL399298A1 (pl) Kompozycja farmaceutyczna do stosowania miejscowego zawierajaca acyklowir oraz sposób jej wytwarzania
TN2013000128A1 (en) Process for preparing pan-cdk inhibitors of the formula (1), and intermediates in the preparation
UA118572C2 (uk) СПОСІБ ОДЕРЖАННЯ 19-НОРПРЕГН-4-ЕН-3,20-ДІОН-17(α)-ОЛУ (ГЕСТОНОРОНУ) І ПРОМІЖНІ ПРОДУКТИ ДЛЯ НЬОГО
UA91166C2 (en) use of ethyl ether N-[(2-oxoindolylinylydene-3)-2-oxyacetyl]-aminoacetic acid of the general formula as nootropic and anxyolytic agent

Legal Events

Date Code Title Description
FG Grant or registration